Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Original Publication: Chicago, IL : American Medical Association, [2018]-

Hospitalization* ; Vaccine Efficacy*; Ad26COVS1/*therapeutic use ; BNT162 Vaccine/*therapeutic use ; COVID-19/*prevention & control ; COVID-19 Vaccines/*administration & dosage ; SARS-CoV-2/*immunology; Aged ; Aged, 80 and over ; Comparative Effectiveness Research ; Female ; France/epidemiology ; Humans ; Male ; Middle Aged ; Population Health

Lancet Reg Health Eur. 2021 Sep;8:100158. (PMID: 34308411)
JAMA Netw Open. 2021 Nov 1;4(11):e2132540. (PMID: 34726743)
N Engl J Med. 2021 Oct 7;385(15):1355-1371. (PMID: 34496194)
Lancet. 2021 Oct 16;398(10309):1407-1416. (PMID: 34619098)
N Engl J Med. 2021 Jun 10;384(23):2187-2201. (PMID: 33882225)

JT2NS6183B (Ad26COVS1)
0 (COVID-19 Vaccines)
N38TVC63NU (BNT162 Vaccine)

Date Created: 20220302 Date Completed: 20220311 Latest Revision: 20221207

20240628

PMC8892225

10.1001/jamanetworkopen.2022.0868

35234883